CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 75 enrolled
Drug / intervention
Testopel 75mg Drug Implant +2 moredrug
Likely dose
Testopel 75mg Drug Implantfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04523480
NCT04523480Phase 3Completed
CompareCT.gov

Randomized Control Trial of Long Acting Subcutaneous Testosterone Pellets for Hypogonadism: Testopel ® vs. Generic Testosterone Pellets.

University of Miami·interventional·Posted Aug 21, 2020·Updated Aug 14, 2023

In Brief

A Phase 3 clinical trial evaluating Testopel 75mg Drug Implant, Testopel 100mg Drug Implant, and 1 other intervention for Hypogonadism. Completed, enrolled 75 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate changes in vascular parameters in subjects receiving Testopel 75mg (one time) versus subjects receiving Compounded Testosterone pellets 100mg (one time) versus subjects receiving Compounded Testosterone pellets 200mg (one time) to participant with clinical hypogonadism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
CollaboratorsEmpower Research Inc

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedAug 21, 2020
Enrollment StartMar 12, 2020
Primary CompletionDec 20, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.9 years ago

Interventions

Testopel 75mg Drug Implantdrug

75 mg Testosterone pellets administered subcutaneously.

Testopel 100mg Drug Implantdrug

100 mg Testosterone pellets administered subcutaneously.

Testopel 200mg Drug Implantdrug

200 mg Testosterone pellets administered subcutaneously.